Table IV.
Assessment of LAGE-1b–specific serum Abs in patients with advanced melanoma
| Peptides |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
| Patients | LAGE-1b132–149 | LAGE-1b139–156 | LAGE-1b146–163 | LAGE-1b153–170 | LAGE-1b160–177 | LAGE-1b167–184 | LAGE-1b181–198 | LAGE-1b188–210 | NY-ESO-1 |
| MP1 | – | – | – | – | – | – | – | – | +++ |
| MP2 | – | – | – | – | – | – | – | – | +++ |
| MP3 | – | – | – | – | – | – | – | – | +++ |
| MP4 | – | – | – | – | – | – | – | – | +++ |
| MP5 | – | – | – | – | – | ++ | – | ++ | +++ |
| MP6 | – | ++ | – | – | ++ | ++ | – | ++ | ++ |
| MP7 | – | – | – | – | – | ++ | – | ++ | +++ |
| MP8 | – | – | – | – | – | – | – | – | +++ |
| MP9 | – | ++ | – | – | ++ | ++ | – | ++ | +++ |
| MP10 | – | – | – | – | – | – | – | – | +++ |
| MP11 | – | – | – | – | – | – | – | – | +++ |
| MP12 | – | – | – | – | – | – | – | – | +++ |
| MP13 | – | – | – | – | – | – | – | – | +++ |
| MP14 | – | – | – | – | – | – | – | – | +++ |
| MP15 | – | – | – | – | – | – | – | – | +++ |
| MP16 | – | – | – | – | – | – | – | – | ++ |
| MP17 | – | – | – | – | – | – | – | – | – |
| MP18 | – | – | – | – | – | – | – | – | – |
| MP19 | – | – | – | – | – | – | – | – | – |
| MP20 | – | – | – | – | – | – | – | – | – |
| MP21 | – | – | – | – | – | – | – | – | – |
−, Mean of patient sample at 1/400 dilution < (mean [negative control-normal donor] + 3 SD at 1:400 dilution); +, mean of patient sample at 1/400 dilution > (mean [negative control-normal donor] + 3 SD at 1/400 dilution); ++, mean of patient sample at 1/1600 dilution > (mean [negative control-normal donor] + 3 SD at 1/400 dilution); +++, mean of patient sample at 1/6400 dilution > (mean [negative control-normal donor] + 3 SD at 1/400 dilution).